Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab

David S Kirwin1, Travis Frantz1, Colin F Nolan2

  • 1Naval Medical Center San Diego, San Diego, California, USA.

Pediatric Dermatology
|April 14, 2025
PubMed

Insights

Pediatric generalized pustular psoriasis (GPP) is a rare condition. A new study identifies Mediterranean fever gene (MEFV) variants as a risk factor, highlighting the need for genetic research in childhood autoinflammatory diseases.

Area of Science:

  • Pediatric Dermatology
  • Genetics
  • Immunology

Background:

  • Pediatric generalized pustular psoriasis (GPP) is a rare, severe childhood skin condition.
  • Early-onset GPP is often linked to interleukin-36 receptor antagonist (DITRA) deficiency.

Observation:

  • A case study involved a pediatric patient diagnosed with GPP.
  • The patient was found to have a heterozygous variant in the Mediterranean fever gene (MEFV).

Findings:

  • MEFV variants represent a newly identified genetic risk factor for GPP.
  • The patient's GPP was successfully treated with adalimumab.

Implications:

  • This case underscores the importance of genomic studies in pediatric autoinflammatory diseases.
  • Evidence-based management strategies are crucial for challenging pediatric GPP cases.